- Home
- FORA vs BNTC Comparison
FORA vs BNTC Comparison
Compare FORA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- BNTC
- Stock Information
- Founded
- FORA 2014
- BNTC 1995
- Country
- FORA United States
- BNTC United States
- Employees
- FORA N/A
- BNTC N/A
- Industry
- FORA Computer Software: Prepackaged Software
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- BNTC Health Care
- Exchange
- FORA Nasdaq
- BNTC Nasdaq
- Market Cap
- FORA 66.1M
- BNTC 366.6M
- IPO Year
- FORA N/A
- BNTC N/A
- Fundamental
- Price
- FORA $2.05
- BNTC $12.89
- Analyst Decision
- FORA Strong Buy
- BNTC Strong Buy
- Analyst Count
- FORA 1
- BNTC 6
- Target Price
- FORA $5.00
- BNTC $23.83
- AVG Volume (30 Days)
- FORA 7.5K
- BNTC 234.8K
- Earning Date
- FORA 08-13-2025
- BNTC 05-14-2025
- Dividend Yield
- FORA N/A
- BNTC N/A
- EPS Growth
- FORA N/A
- BNTC N/A
- EPS
- FORA N/A
- BNTC N/A
- Revenue
- FORA $22,332,001.00
- BNTC N/A
- Revenue This Year
- FORA $46.25
- BNTC N/A
- Revenue Next Year
- FORA $11.30
- BNTC N/A
- P/E Ratio
- FORA N/A
- BNTC N/A
- Revenue Growth
- FORA 5.22
- BNTC N/A
- 52 Week Low
- FORA $1.85
- BNTC $7.05
- 52 Week High
- FORA $4.03
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- FORA 49.88
- BNTC 50.13
- Support Level
- FORA $1.96
- BNTC $12.57
- Resistance Level
- FORA $2.21
- BNTC $13.88
- Average True Range (ATR)
- FORA 0.12
- BNTC 1.18
- MACD
- FORA 0.00
- BNTC 0.02
- Stochastic Oscillator
- FORA 33.33
- BNTC 62.63
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.